Evoke Wealth’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-31,542
| Closed | -$635K | – | 352 |
|
|
2026
Q1 | $635K | Sell |
31,542
-299
| -0.9% | -$4.82K | 0.01% | 361 |
|
|
2025
Q4 | $514K | Sell |
31,841
-212
| -0.7% | -$2.81K | 0.01% | 384 |
|
|
2025
Q3 | $390K | Sell |
32,053
-128
| -0.4% | -$1.77K | 0.01% | 430 |
|
|
2025
Q2 | $364K | Sell |
32,181
-265
| -0.8% | -$3.24K | 0.01% | 409 |
|
|
2025
Q1 | $374K | Buy |
32,446
+83
| +0.3% | +$847 | 0.01% | 318 |
|
|
2024
Q4 | $274K | Hold |
32,363
| – | – | 0.01% | 359 |
|
|
2024
Q3 | $375K | Buy |
32,363
+16,990
| +111% | +$214K | 0.01% | 303 |
|
|
2024
Q2 | $181K | Buy |
+15,373
| New | +$179K | 0.21% | 88 |
|
|
2023
Q1 | – | Sell |
-25,583
| Closed | -$173K | – | 365 |
|
|
2022
Q4 | $173K | Hold |
25,583
| – | – | 0.01% | 341 |
|
|
2022
Q3 | $371K | Hold |
25,583
| – | – | 0.02% | 241 |
|
|
2022
Q2 | $252K | Hold |
25,583
| – | – | 0.01% | 286 |
|
|
2022
Q1 | $377K | Hold |
25,583
| – | – | 0.01% | 261 |
|
|
2021
Q4 | $338K | Buy |
+25,583
| New | +$407K | 0.01% | 287 |
|
Other funds holding KALV
Evoke Wealth's KALV Position: Q2 2026 in Review
Evoke Wealth sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 31,542 shares — an estimated $635K sold.
Evoke Wealth first reported a position in KALV in Q4 2021 and held it in 13 quarters. The position peaked at $635K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Evoke Wealth reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Evoke Wealth sold 31,542 KalVista Pharmaceuticals shares in Q2 2026, an estimated $635K.
- Evoke Wealth first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 13 quarters.
- Evoke Wealth's KalVista Pharmaceuticals position peaked at $635K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.